Lin Oscar, Cardillo Marina, Dalbagni Guido, Linkov Irina, Hutchinson Brian, Reuter Victor E
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Mod Pathol. 2003 Dec;16(12):1289-98. doi: 10.1097/01.MP.0000094091.04541.FC.
Nested variant of urothelial carcinoma is characterized by confluent small nests and abortive tubules of mildly atypical neoplastic cells infiltrating the lamina propria and/or muscularis propria of the bladder. Despite its deceptively bland histomorphologic appearance, the lesion is reported to have an aggressive behavior. The collective immunohistochemical expression of suppressor genes, growth factor, and proliferation activity marker has not been previously studied in this disease. Formalin-fixed, paraffin-embedded archival tissues from 12 cases of nested variant of urothelial carcinoma were stained with monoclonal antibodies to p21, p27, p53, EGF-R, and bcl-2, as well as the proliferation marker MIB-1. The area of predominant immunoreactivity was also evaluated. The pattern of immunostaining was compared with the clinical parameters. p21 was positive in 10 of 12 cases and located at the deepest portion of the tumor in 5 of 10 positive cases. Immunoreactivity for p27 was seen in 11 of 12 cases and limited to the superficial portion of the tumor in 9 of 11 positive cases. Only 3 and 2 of 12 cases were positive for p53 and bcl-2, respectively. MIB-1 immunoreactivity ranged from 2 to 35% of the neoplastic cells, with most tumors showing a proliferation index of >15%. Follow-up ranged from 3 to 30 months (mean, 17.6 mo). All patients except one were alive, although three patients developed metastases. Nested variant of urothelial carcinoma is a deceptively benign-appearing neoplasm with potential of deep invasion and metastases. Immunohistochemically, nested variant of urothelial carcinoma shares some features with high-risk conventional urothelial carcinomas, such as loss of p27 expression and high proliferation index. Nevertheless, p53, bcl-2, or EGF-r immunoreactivity is not frequently seen.
尿路上皮癌巢状变异型的特征是由融合的小巢状结构和发育不全的小管组成,其中轻度非典型性肿瘤细胞浸润膀胱固有层和/或肌层。尽管其组织形态学表现看似温和,但据报道该病变具有侵袭性。此前尚未对该疾病中抑制基因、生长因子和增殖活性标志物的免疫组化表达进行过研究。对12例尿路上皮癌巢状变异型的福尔马林固定、石蜡包埋存档组织进行免疫组化染色,使用针对p21、p27、p53、表皮生长因子受体(EGF-R)和bcl-2的单克隆抗体,以及增殖标志物MIB-1。还评估了主要免疫反应性区域。将免疫染色模式与临床参数进行比较。12例中有10例p21呈阳性,10例阳性病例中有5例位于肿瘤最深部。12例中有11例可见p27免疫反应性增强,11例阳性病例中有9例局限于肿瘤浅表部分。12例中分别只有3例和2例p53和bcl-2呈阳性。MIB-1免疫反应性在肿瘤细胞中占2%至35%,大多数肿瘤的增殖指数>15%。随访时间为3至30个月(平均17.6个月)。除1例患者外,所有患者均存活,尽管有3例患者发生了转移。尿路上皮癌巢状变异型是一种看似良性但具有深层浸润和转移潜能的肿瘤。免疫组化显示,尿路上皮癌巢状变异型与高危传统尿路上皮癌有一些共同特征,如p27表达缺失和高增殖指数。然而,p53、bcl-2或EGF-r免疫反应性并不常见。